drugset / Trial / NCT02607449
FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis
Phase 3
Completed
344 enrolled
Scientific Center for Anti-infectious Drugs, Kazakhstan
Invivo laboratory, Kazakhstan · collabKaraganda Medical University · collabNational Center of Phthisiatry, Bishkek, Kyrgyzstan · collabNational Scientific Center of Phthisiopulmonology, Kazakhstan · collabPhthisiopulmonology Center of Almaty, Kazakhstan · collabSemey State Medical University · collabWest Kazakhstan Marat Ospanov Medical University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Drug-resistant tuberculosis is becoming a major problem for the whole humanity, and development of new Anti-TB drugs is of great importance. Since Kazakhstan is a country with the high burden of tuberculosis, the Government of the Republic of Kazakhstan has founded initiative on the development of new Anti-TB drug to treat drug-resistant forms of this infectious disease. JSC "Scientific Center for Anti-infectious Drugs" has developed original drug FS-1 for the treatment of multidrug resistant tuberculosis (MDR-TB).
Timeline
- Start
- 2013-12
- Primary completion
- 2020-08
- Completion
- 2020-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FS-1 | Unknown | 2.5 mg/kg | Oral |